Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that the Company's management team will host a quarterly update conference call with a live webcast for investors, analysts and other interested parties. During the conference call, the Company will provide a corporate update and discuss the clinical and regulatory progress for its in-house product candidates, as well as those being developed with Xenetic's biotechnology and pharmaceutical partners. Xenetic's current in-house product pipeline includes Virexxa® (sodium cridanimod), which is being evaluated for the treatment of endometrial cancer and triple negative breast cancer, and ErepoXen™, a polysialylated form of erythropoietin (EPO), a hormone created by the kidneys to maintain red blood cell production and prevent anemia. Xenetic is also currently evaluating OncoHist™ for the treatment of acute myeloid leukemia (AML) in refractory patients and refractory non-Hodgkin lymphoma (NHL). Conference Call and Webcast Information Xenetic management will host a conference call for investors, analysts and other interested parties on Wednesday, November 30, 2016 at 8:30 a.m. ET. The conference call and live webcast will be accompanied by presentation slides. To participate in the call, please dial (877) 407-6914 (domestic) or (201) 493-6709 (international). The live webcast and accompanying slides will be available by accessing the IR Calendar in the Investors section of Xenetic's website ( www.xeneticbio.com). A replay of the webcast will be available for 90 days, starting approximately two hours after the presentation ends. About Xenetic Biosciences Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen®, designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs.